Status:
COMPLETED
Effect of Diltiazem Administration on CP-945,598 Pharmacokinetics
Lead Sponsor:
Pfizer
Conditions:
Obesity
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
A recently completed clinical drug interaction study of CP-945,598 with ketoconazole, a potent CYP3A inhibitor, showed that coadministration of CP-945,598 with ketoconazole results in an approximately...
Eligibility Criteria
Inclusion
- No clinically relevant abnormalities based upon medical history, physical exam, 12-lead ECG, and clinical lab tests
- Body Mass Index (BMI) \~ 27-40 kg/m2, inclusive
- Personally signed inform consent document
Exclusion
- Evidence or history of significant acute or chronic disease
- Pregnant or nursing females
- Screening PR interval \> 220 msec
- Sitting blood pressure \<= 90 mmHg systolic or \<= 60 mmHg diastolic
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2007
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT00645463
Start Date
March 1 2007
End Date
June 1 2007
Last Update
September 17 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Ann Arbor, Michigan, United States, 48105